These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33109026)

  • 21. Current advances in the development of SARS-CoV-2 vaccines.
    Awadasseid A; Wu Y; Tanaka Y; Zhang W
    Int J Biol Sci; 2021; 17(1):8-19. PubMed ID: 33390829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS - CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis).
    Ietto G
    Med Hypotheses; 2020 Aug; 141():109779. PubMed ID: 32387756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2: vaccines in the pandemic era.
    Li DD; Li QH
    Mil Med Res; 2021 Jan; 8(1):1. PubMed ID: 33402220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward.
    Vashishtha VM; Kumar P
    Hum Vaccin Immunother; 2021 Jun; 17(6):1635-1649. PubMed ID: 33270478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scrutinizing the SARS-CoV-2 protein information for designing an effective vaccine encompassing both the T-cell and B-cell epitopes.
    Jain N; Shankar U; Majee P; Kumar A
    Infect Genet Evol; 2021 Jan; 87():104648. PubMed ID: 33264668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug Discovery Strategies for SARS-CoV-2.
    Shyr ZA; Gorshkov K; Chen CZ; Zheng W
    J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control.
    Salvamani S; Tan HZ; Thang WJ; Ter HC; Wan MS; Gunasekaran B; Rhodes A
    Br J Biomed Sci; 2020 Oct; 77(4):168-184. PubMed ID: 32942955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Super-rapid race for saving lives by developing COVID-19 vaccines.
    Uttarilli A; Amalakanti S; Kommoju PR; Sharma S; Goyal P; Manjunath GK; Upadhayay V; Parveen A; Tandon R; Prasad KS; Dakal TC; Ben Shlomo I; Yousef M; Neerathilingam M; Kumar A
    J Integr Bioinform; 2021 Mar; 18(1):27-43. PubMed ID: 33761582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19.
    Singh N; Rai SN; Singh V; Singh MP
    J Chem Neuroanat; 2020 Dec; 110():101874. PubMed ID: 33091590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.
    Tahir Ul Qamar M; Shahid F; Aslam S; Ashfaq UA; Aslam S; Fatima I; Fareed MM; Zohaib A; Chen LL
    Infect Dis Poverty; 2020 Sep; 9(1):132. PubMed ID: 32938504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years.
    Saad-Roy CM; Wagner CE; Baker RE; Morris SE; Farrar J; Graham AL; Levin SA; Mina MJ; Metcalf CJE; Grenfell BT
    Science; 2020 Nov; 370(6518):811-818. PubMed ID: 32958581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.
    Ma C; Su S; Wang J; Wei L; Du L; Jiang S
    Microbes Infect; 2020; 22(6-7):245-253. PubMed ID: 32437926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds.
    Moore JP; Klasse PJ
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32591466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.
    Flanagan KL; Best E; Crawford NW; Giles M; Koirala A; Macartney K; Russell F; Teh BW; Wen SC
    Front Immunol; 2020; 11():579250. PubMed ID: 33123165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 Vaccines in Clinical Trials and their Mode of Action for Immunity against the Virus.
    Tavakol S; Alavijeh MS; Seifalian AM
    Curr Pharm Des; 2021; 27(13):1553-1563. PubMed ID: 33100195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targets and strategies for vaccine development against SARS-CoV-2.
    Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
    Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?
    Gemmati D; Bramanti B; Serino ML; Secchiero P; Zauli G; Tisato V
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32423094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pivotal roles of the host immune response in the fine-tuning the infection and the development of the vaccines for SARS-CoV-2.
    Alturaiki W; Mubarak A; Al Jurayyan A; Hemida MG
    Hum Vaccin Immunother; 2021 Oct; 17(10):3297-3309. PubMed ID: 34114940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the Immune Microenvironment in SARS-CoV-2 Infection.
    Ye CH; Hsu WL; Peng GR; Yu WC; Lin WC; Hu S; Yu SH
    Cell Transplant; 2021; 30():9636897211010632. PubMed ID: 33949207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.